MediPharm Labs (LABS) Stock Overview
Operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LABS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
MediPharm Labs Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.07 |
| 52 Week High | CA$0.12 |
| 52 Week Low | CA$0.06 |
| Beta | 0.75 |
| 1 Month Change | -12.50% |
| 3 Month Change | -22.22% |
| 1 Year Change | -6.67% |
| 3 Year Change | -12.50% |
| 5 Year Change | -87.27% |
| Change since IPO | -96.82% |
Recent News & Updates
Recent updates
MediPharm Labs Corp. (TSE:LABS) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Aug 14
MediPharm Labs Corp.'s (TSE:LABS) Shares Leap 54% Yet They're Still Not Telling The Full Story
Mar 26MediPharm Labs Corp. (TSE:LABS) Doing What It Can To Lift Shares
Oct 11MediPharm Labs (TSE:LABS) Is Using Debt Safely
May 29Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost
Mar 23Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Jan 10MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?
Sep 06MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 17Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook
Aug 20Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates
May 21Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade
Apr 06Is MediPharm Labs (TSE:LABS) Using Too Much Debt?
Mar 07Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?
Aug 18Shareholder Returns
| LABS | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | 4.1% | 2.3% |
| 1Y | -6.7% | 2.2% | 19.5% |
Return vs Industry: LABS underperformed the Canadian Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: LABS underperformed the Canadian Market which returned 18.2% over the past year.
Price Volatility
| LABS volatility | |
|---|---|
| LABS Average Weekly Movement | 12.6% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in CA Market | 19.9% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: LABS has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: LABS's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 161 | David Pidduck | www.medipharmlabs.com |
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products.
MediPharm Labs Corp. Fundamentals Summary
| LABS fundamental statistics | |
|---|---|
| Market cap | CA$29.45m |
| Earnings (TTM) | -CA$8.66m |
| Revenue (TTM) | CA$44.45m |
Is LABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LABS income statement (TTM) | |
|---|---|
| Revenue | CA$44.45m |
| Cost of Revenue | CA$29.85m |
| Gross Profit | CA$14.60m |
| Other Expenses | CA$23.26m |
| Earnings | -CA$8.66m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 13, 2025
| Earnings per share (EPS) | -0.021 |
| Gross Margin | 32.84% |
| Net Profit Margin | -19.47% |
| Debt/Equity Ratio | 1.1% |
How did LABS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/11 05:33 |
| End of Day Share Price | 2025/11/11 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MediPharm Labs Corp. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Tamy Chen | BMO Capital Markets Equity Research |
| Kimberly Thompson-Hedlin | Canaccord Genuity |